Mithra Demonstrates Further Estetrol’s Unique Profile at the Annual Meeting of the Endocrine Society

Liege, Belgium, 25 March 2019 – 7 :30  CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health has presented the results of a new study on Estetrol (E4) at the 101st Annual Meeting of the Endocrine Society (ENDO 2019) held from March 23 to 26 in New Orleans (U.S.)

 

Mithra Signs License and Supply Agreement for Commercialization of Tibelia® in Chile

  • Mithra strengthens its presence in the fast-growing Chilean market with an agreement for commercialization of the hormone treatment Tibelia® with Saval Pharmaceuticals
  • Tibelia® is currently marketed in about ten countries through existing license and supply agreements and just adds an additional market in Spain after winning a public tender

Liege, Belgium, 05 March 2019 – 7 :30  CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, announces that it has entered into a license and supply agreement with Saval Pharmaceuticals to commercialize Tibelia® in Chile.

Mithra Reports 2018 Annual Results

  • Strong revenue growth (+42%) with significantly improved EBITDA (record level of EUR 38.3 M vs. EUR -18.4 M in 2017) and cash position (EUR 119 M vs. EUR 36.2 M in 2017) thanks to increased business development activities
  • Strengthening Mithra’s international deployment through key partnerships with women’s health leaders
  • Clinical milestones successfully achieved for highly promising portfolio E4 (Estetrol)-based pipeline, including the 5th generation contraceptive pill Estelle® and next-generation menopause therapy Donesta®
  • Additional potential E4-based blockbuster for the underserved perimenopause market with PeriNesta™ in development (which brings Mithra’s late clinical stage pipeline to a total of 3)

Liege, Belgium, 01 March 2019– 7 :30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces its results for the year ended 31 December 2018, prepared in accordance with IFRS.